Delivery Order SPE2DB22D3016-SPE2DB25FBGT4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in a 120 ml unit at a firm fixed price of $1,263.27. This is an unset-aside, competitively awarded delivery order with an ultimate completion date of June 25, 2025, to be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in 120ml quantities, with a ceiling value of $5,053.08 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of October 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,684.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Hemangeol 4.28 mg/mL oral solution (120 mL) on May 30, 2025, with an ultimate completion date of June 23, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $2,196.60 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 120ml bottles of 4.28mg/ml oral solution of HEMANGEOL under contract number 4562076621. As the prime contractor, Amerisourcebergen Drug Corporation will deliver the requested pharmaceutical product from its facility in Conshohocken, Pennsylvania for use by the Department of Defense between September 5th and 26th, 2023. The delivery order was awarded against the Defense...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $1,656.80 firm fixed price contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has a completion date of May 8, 2024 and does not have a set-aside designation. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has a ceiling value of $1,684.36 and is a Firm Fixed Price arrangement. The period of performance extends to July 16, 2025. This appears to be an order under a larger Indefinite Delivery Contract (IDC) held by...
- This is a delivery order (SPE2DB24FBC04) issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp Corporate Office Division under the DLA Troop Support Medical Indefinite Delivery Contract (IDC) valued at up to $999,999,999. The order is for the specialty pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, with a ceiling value of $1,656.80 and a delivery date of August 23, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this...
- The Defense Logistics Agency awarded a delivery order valued at $3,401.50 to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically AMLOD-VALSA-HCTZ 10-320-25 MG in a 30-count supply. This firm fixed-price delivery order, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no...
- The Defense Logistics Agency awarded a delivery order valued at $1,316.47 to AmerisourceBergen Drug Corp for the supply of Hydralazine 20 mg/mL vials. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $26,451.57 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 150 mg/ml vials. This firm fixed price contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGT4Delivery Order
The Defense Logistics Agency awarded a $10,106.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Hemangeol 4.28 mg/mL oral solution (120 mL) on August 29, 2025, with completion targeted for September 22, 2025. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitive award. Hemangeol is a beta-blocker solution used primarily in the treatment of infantile hemangioma, a common benign vascular tumor in infants. As a critical pharmaceutical distributor supporting federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to military and veteran healthcare systems through its DLA partnership. This delivery order represents one component of the company's extensive portfolio supporting the Defense Health Agency and other federal healthcare programs through a flexible global pharmaceutical supply vehicle designed to ensure consistent access to specialty medications across the military healthcare network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 8/29/25 |